Lucid Group Company
Lucid aims to develop a unique 3 in one diagnostic device. The device would help intuitive, fast and economic measure biophysiological markers (pressure, sensation and muscle contractility вАУ via EMG), enabling more precise diagnosis of the functional deficits in faecal incontinence at primary care.
Investors
Connections from
Total Funding:
£719 947
Headquarters:
Manchester, Manchester, United Kingdom
Funding Status:
Private
Employee Number:
11-50
Estimated Revenue:
< £780 000
Last Funding Type:
Grant
Last Funding Date:
02-01-2015
Investors Number:
4
Founded Date:
2002
Industry:
P4 medicine